Effect of dopamine and dopamine-antagonist infusion on blood platelet count, size and release reaction in hypertensive and normotensive subjects

Scand J Clin Lab Invest. 1989 Jun;49(4):307-15. doi: 10.3109/00365518909089102.

Abstract

To examine the effect of dopamine on in vivo platelet function and a possible platelet contribution to the clearance of dopamine we measured platelet count, platelet size and plasma concentration of the platelet specific protein beta-thromboglobulin (BTG) in groups of 40 year old untreated hypertensive and normotensive men. One hypertensive (n = 10) and one normotensive (n = 10) group received dopamine infusion at doses from 0.5 to 2.0 micrograms/kg/min which increased plasma dopamine 100-fold from baseline. Two other groups of hypertensive (n = 10) and normotensive (n = 11) subjects received 10 mg of the dopamine antagonist metoclopramide intravenously, upon which serum prolactin concentration increased 10-fold. No significant effect on platelet function in any group was observed during these interventions. Platelet phenol-sulphotransferase may contribute to dopamine conjugation. However, the selected platelet parameters correlated only weakly with dopamine kinetics during the infusion. Neither dopamine nor a dopamine antagonist altered the selected platelet parameters, nor did these parameters influence the clearance of dopamine during a short-lasting pharmacological infusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets / drug effects*
  • Dopamine / administration & dosage*
  • Dopamine / blood
  • Humans
  • Hypertension / blood*
  • Infusions, Intravenous
  • Male
  • Metoclopramide / administration & dosage*
  • Platelet Count / drug effects
  • Prolactin / blood
  • Receptors, Dopamine / drug effects
  • beta-Thromboglobulin / analysis

Substances

  • Receptors, Dopamine
  • beta-Thromboglobulin
  • Prolactin
  • Metoclopramide
  • Dopamine